替罗非班联合重组人脑利钠肽治疗急性心肌梗死伴心力衰竭患者的疗效分析  

Study on clinical outcome of tirofiban combined recombinant human brain natriuretic peptide in acute myocardial infarction with heart failure

作　　者：许圆圆[1] 支继新[1] 孙超宇[1] 孙丽秀[1] 侯凤丽[1] 李学奇[1] 

机构地区：[1]哈尔滨医科大学附属第四临床医学院心血管内科六病房,黑龙江哈尔滨150001

出　　处：《中国急救医学》2013年第4期330-332,共3页Chinese Journal of Critical Care Medicine

摘　　要：目的探讨替罗非班与重组人脑利钠肽（rhBNP）联合对于急性心肌梗死（AMI）伴心力衰竭患者的疗效。方法AMI合并心力衰竭患者94例随机分为常规治疗组（A组）：给予利尿、扩血管、阿司匹林及氯吡格雷等常规治疗；替罗非班＋rhBNP组（B组）：在常规治疗方案基础上，应用盐酸替罗非班，给予的剂量：0．4μg／／（kg·min），30min后以0．1μg/（kg·min）微量泵静脉持续泵入48h；同时应用rhBNP，给予的剂量：1．5μg/kg，3min后以0．015μg／（kg·min）微量泵静脉持续泵入48h。比较两组用药前后各项指标。结果入院时两组CK-MB、TnI、SCr、NT-proBNP值水平差异无统计学意义（P〉0．05）；治疗后两组CK-MB、TnI、SCr、NT-proBNP值水平较治疗前均有下降（P〈0．05），B组下降更明显（P〈0．05）；治疗后两组LVDD均有所下降，LVEF水平较治疗前明显升高（P〈0．05），B组更明显（P〈0．05）。结论替罗非班联合rhBNP治疗AMI伴心力衰竭患者疗效确切。Objective To investigation the effects of tirofiban combined recombinant human brain natriuretic peptide（rhBNP） in acute myocardial infarction with heart failure. Methods A total of 94 patients with AMI and heart failure were randomly divided into two groups. Group A： conventional therapy, such as diuretic, vasodilator, aspirin and clopidogrel; Group B： conventional therapy ＋ tirofiban ＋ rhBNP. And then CK- MB, troponin I（TnI）, SCr, N -terminal B- type natriuretic peptide （ NT - proBNP）, left ventricular end - diastolic diameter （LVDD） and LVEF were measured before and after treatment. Results Levels of Group B of CK - MB, TnI, SCr, NT - proBNP, LVDD were decreased significantly compared with Group A, LVEF were increased. Conclusion For tirofiban combined with recombinant human brain natriuretic peptide treatment of AMI with heart failure efficacy.

关 键 词：替罗非班 重组人脑利钠肽(rhBNP) 急性心肌梗死(AMI) 心力衰竭(HF) 

分 类 号：R973.2[医药卫生—药品]